Aurora Mobile Limited (NASDAQ: JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services in China, today announced that its push notification ...

Interactive Brokers Group, Inc. (NASDAQ:IBKR – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock traders bought 3,850 call options on the company. This is ...

Aurora Cannabis Inc. closed 58.72% short of its 52-week high of $9.35, which the company reached on April 30th.

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to ...

Sunrise Center clubhouse, with leasing offices, is scheduled to be delivered 45 days prior to the first residential building to assist in leasing activities. That building already has drywall ...

Shares of Aurora Cannabis Inc. ACB advanced 1.30% to $3.90 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.64% to ...

In a recent filing with the Securities and Exchange Commission, Old Second Bancorp Inc. (NASDAQ:OSBC) disclosed that its ...

ZenseAI, powered by GPTBots.ai's advanced AI solutions, empowers schools to provide personalized teaching tailored to individual student needs. It also reduces the administrative workload for ...

The success of ZenseAI underscores the transformative potential of AI in education and paves the way for innovative teaching models within the Hong Kong market. Meta Dot is committed to enhancing ...

NICE (NASDAQ:NICE – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. A number of other ...

Aurora Cannabis Inc. (NASDAQ:ACB – Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 4,520,000 shares, a growth of 5.9% ...

Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May ...